Wed, Aug 20, 2014, 2:12 AM EDT - U.S. Markets open in 7 hrs 18 mins

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • wilderguide wilderguide Jun 25, 2013 9:48 AM Flag

    Ganetespib & PD-1 inhibition

    $$$$
    From the June 2013 revision to the SNTA website's corporate presentation...
    This portion of the presentation appears to have been added recently.
    Interesting that it's appearance is coincidental to recent insider buying.
    A PR might provide some entertaining catalyst...
    GLTA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Do you think you could do me a favor and cut and paste that part that was updated.

      My computer for some reason wont let me view that pdf file.

      And BTW was that updated today ?????

      • 1 Reply to lilgodfther
      • $$$$
        A copy and paste won't work. The presentation is a graph with a biblioraphical reference to three research papers, which I took some time to review today. I can't find verification that any preclinical work has taken place wrt ganetespib and PD-1 inhibition. The rationale for such a work-up has been suggested, but to my knowledge, not actually initiated. Check out: "Combination therapy with HSP90i 17-DMAG reconditions the tumor micro environment to improve recruitment of therapeutic T cells"

        I also cruised the clinicltrialsdotgov site, checking all the advanced PD-1 inhibitor sites for early trial work-ups. I could find nothing w/ Nivolumab, lambrolizumb, MPDL-3280A, or CT-011. To my knowledge, there are no other PD-1 inhibitors that might qualify. I think SNTA has some explaining to do wrt the presentation. If any preclinical work has been done w ganetespib and PD-1 inhibition, that work has yet to be presented and published. JMHO - but I figure we are awaiting a news release to explain the omission.
        GLTA

 
SNTA
4.03-0.04(-0.98%)Aug 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.